Progressive thyroid lymphocytic infiltration in a patient with chronic hepatitis

Infiltración linfocitaria progresiva tiroidea en paciente con hepatopatía crónica

We report the case of a 53-year-old woman with a personal history of chronic venous insufficiency and recurrent biliary colic who was seen after goiter was detected at routine medical visit. A physical examination revealed diffuse grade 3 goiter associated with two to four bilateral hard nodules attached to deep planes. There were no adenopathies. No thyroid tenderness or other findings were made during the physical examination. Laboratory test results included: liver enzymes: GGT, 69 IU/L; GPT, 53 UI/L; GGT, 360 IU/L; AP, 2429 IU/L. Thyroid hormones: TSH, 4.16 μU/mL; FT4, 1.07 ng/dL. Anti-thyroid antibodies (anti-thyroglobulin and anti-thyroperoxidase): negative. Acute phase reactants: C-reactive protein, 33.5 mg/L; ESR: 73 mm/h.

Thyroid ultrasound examination: four solid, hypoechoic, non-vascularized nodules 2–5 cm in size were seen, two in each nodule. The predominant nodule, 5 cm in size, was found in the middle portion of the right lobe. Fine needle aspiration: puncture of the dominant nodule was inadequate for cytological study. The patient was therefore referred for endocrine surgery because of nodule size. During surgery, a mass of a woody consistency was found, closely adherent to adjacent tissues, which prevented complete resection. Pathological study of surgical specimen. Gross examination: left lobe: brown whitish triangular fragment 1.5 cm in size of elastic consistency, with no normal thyroid tissue upon sectioning.

Right lobe: triangular fragment 1.5 cm in size with similar characteristics to the left fragment. Immunohistochemistry: CD-3 and CD-20: positive scattered lymphoid infiltrate.

Kappa and lambda light chains: positive in plasmacellular infiltrate. Cytokeratin pan: negative. Thyroglobulin: positivity for vestiges of thyroid follicles. Microscopic examination: sections showed thyroid tissue in both lobes to be widely replaced by collagenized fibrous tissue, marked thyroid follicle atrophy, and marked infiltration of mononuclear inflammatory cells (Fig. 1). CT of the neck: diffuse decrease of usual density of thyroid parenchyma, with no invasion of adjacent tissues. Based on these findings in supplemental tests, Riedel’s thyroiditis was diagnosed.

In parallel to thyroid work-up, and based on recurrent episodes of biliary colic, renal colic and urinary infection, associated with intermittent claudication and chronic venous insufficiency, the internal medicine department performed a CT scan of the abdomen and pelvis that revealed portal thrombosis with abundant esophageal varices and perihepatic, perisplenic, and pericolonic collaterals; moderate splenomegaly and a small splenic cyst; right renal atrophy, fibrosis of intrarenal excretory system and right ureter entrapment; distal retroperitoneal and periaortic presacral fibrosis and fibrosis around the iliac vessels with complete obstruction of the iliac and collateral veins through prominent gonadal veins (Fig. 2).

As regards liver involvement, biliary cirrhosis (stage A 5–6) was shown, with portal thrombosis that is still present. Anticoagulation was ruled out because of two episodes of upper gastrointestinal bleeding and melena secondary to rupture of esophageal varices that required hospital admission.

Based on these findings, treatment with prednisone (40 mg/24 h in a cyclic scheme) and tamoxifen (20 mg/day) was prescribed. Two years later, thyroid ultrasound examination showed a significant reduction of the size of the thyroid nodules (which became subcentimetric), a marked improve-

**Figure 1** Microscopic view of surgical specimen.
ment of fibrosis in CT, and subclinical hypothyroidism that required treatment with levothyroxine 50 mcg/day. It should be noted that cholestatic parameters evolved to total normalization after treatment with glucocorticoids and tamoxifen was started.

Currently, the patient is only being treated with levothyroxine 75 mcg/day. Treatment with glucocorticoids and tamoxifen is not required.

Riedel’s disease, also called thyroid fibrosclerosis or fibrosing thyroiditis, is a chronic inflammatory thyroid disease characterized by the replacement of gland parenchyma by fibrous tissue that extends to adjacent structures. The inflammatory infiltrate is a conglomerate of T and B cells, macrophages, eosinophils, and extracellular proteins. Its incidence and prevalence are both low. Its prevalence has been estimated at approximately 0.05% of thyroidectomies, and is four times more common in women aged 30–50 years.¹

Considerable controversy exists regarding its etiology, and there are currently two different views. On the one hand, some authors think that it is an autoimmune condition, a variant of Hashimoto thyroiditis or the last stage of De Quervain thyroiditis, based on the presence of anti-thyroid antibodies in approximately 40–70% of patients and the frequent coexistence of other autoimmune diseases such as Graves’ or Addison’s disease and pernicious anaemia. On the other hand, there are also authors who think that it is a part of a systemic process of fibrosclerosis characterized by fibroblast proliferation through cytokines such as transforming growth factor beta. This contention is supported by the occasional association of retroperitoneal and mediastinal fibrosis, sclerosing cholangitis, and orbital pseudotumor.²

The most common clinical sign is the rapid growth of the thyroid gland, which acquires a stony consistency, eventually causing compressive symptoms such as dysphagia, dysphonia, and dyspnea. The fact that this is the first and virtually the only clinical sign leads the physician to first consider a diagnosis of thyroid lymphoma or anaplastic carcinoma, because these conditions have a greater incidence and prevalence as compared to fibrosing thyroiditis³ or other benign diseases such as subacute De Quervain’s thyroiditis or the fibrous variant of Hashimoto’s thyroiditis.⁴ However, it should be noted that, unlike in lymphoma, in particular, and in anaplastic carcinoma, lymph nodes are not involved in Riedel’s disease.

Laboratory findings do not provide clear indications, because most of the patients have a normal thyroid function, and may show indirect evidence of a systemic fibrosclerosis process with the involvement of other systems. No specific findings are made using ultrasound and subsequent fine needle aspiration, because the sample is inadequate for cytological study in nearly all cases.⁵

Surgical resection and pathological examination of the surgical specimen are therefore required for final diagnosis because in Riedel’s thyroiditis there is an infiltration of thyroid tissue by a conglomerate of eosinophils, T and B cells, and fibroblasts, an absence of necrosis and anaplastic cells (ruling out lymphoma, sarcoma, and anaplastic cancer), an absence of Hürthle cells or oncocyes (ruling out the fibrous variant of Hashimoto’s thyroiditis), and an absence of giant cells (ruling out De Quervain’s thyroiditis).⁶

There are no clinical trials on the treatment of this rare disease. Small-scale studies and case series have reported a good response to glucocorticoids⁶,⁹ because they decrease progressive infiltration, fibrosis, and the destruction of adjacent structures, and also to tamoxifen, an antiestrogen used for breast cancer with fibrosis-inhibiting properties, which acts as a modulator of transforming growth factor beta, promoting the production of extracellular tissue and fibrosis, decreasing mass size by 50% or more, and sometimes achieving complete resolution of the disease.¹⁰

The diagnosis of Riedel’s thyroiditis is therefore difficult in that it is only made after other more prevalent conditions have been ruled out and because partial or total thyroid gland resection is required.

Conflicts of interest

The authors state that they have no conflicts of interest.

References

Tachycardia-induced cardiomyopathy associated to thyroid hormone resistance

Taquimiocardiopatía metabólica asociada a la resistencia a las hormonas tiroideas

A 65-year-old male with a history of fibrothorax of tuberculous origin and chronic obstructive pulmonary diseases with moderate pulmonary artery hypertension was referred to the cardiology department due to frequent palpitations. The patient had stopped smoking 15 years before and had no other toxic habits or cardiovascular risk factors. His family history included a sister with euthyroid goiter, but no other cases of hyperthyroidism. Examination revealed grade II goiter and a rhythmic heart rate of 156 bpm, but was otherwise unremarkable. A 12-lead electrocardiogram showed sinus tachycardia at 140 bpm (Fig. 1). Laboratory tests showed normal TSH levels of 1.99 μU/mL (0.27–5.91) and high levels of FT4 (3.5 ng/dL, 0.8–1.8) and FT3 (6.06 pg/mL, 2.57–4.43), which were confirmed in two subsequent measurements. Twenty-four hour Holter monitoring revealed sinus rhythm with maximum heart rate of 158 bpm and minimum nighttime HR of 60 bpm, with a mean HR of 102 bpm, and monomorphic ventricular extrasystoles of moderate severity with doublets and triplets (Fig. 2).

Echocardiography showed atrial and left ventricular dilation with mild systolic function, tricuspid insufficiency, and severe pulmonary artery hypertension (Table 1). Serologic testing for cardiotropic viruses was negative. Based on the suspicion of hyperthyroidism of a pituitary origin related to persistently elevated thyroid hormones with uncontrolled or inappropriately high TSH, the patient was evaluated by the endocrinology department. The results of baseline pituitary hormone assessment and tests for antithyroid antibodies and thyroid-stimulating immunoglobulins were normal or negative. Glycoprotein hormone subunit α level was 0.41 mU/mL (normal <0.8), with a subunit α/TSH ratio of 0.20. A thyroid ultrasound examination revealed multinodular goiter, and a thyroid scan showed an enlarged gland with low uptake in the lower pole of the left lobe. Gadolinium-enhanced MRI of the sella turcica was normal, and a genetic study of the thyroid hormone receptor beta gene (TRHβ), performed by sequencing exons 7, 8, 9, and 10, was negative. The TRH test was performed with 200 μg IV to measure basal FT4 and TSH at 0, 20, and 60 minutes. A maximum TSH increase to 28 μU/mL was seen at 20 minutes, but decreased to 5.1 μU/mL in a repeat test performed after 10 days of oral treatment with 100 μg of T3 (Werner test). A final diagnosis of tachycardia-induced cardiomyopathy secondary to hyperthyroidism due to selective pituitary resistance to thyroid...